IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR
IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Sponsor Artios Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
Sponsor Phenonet Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
Sponsor Alentis Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR?
The 2026-10-09 snapshot links IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR to 6 distinct CTIS trials. Recorded services include Laboratory services, Direct Coombs Testing, for all patients except US patients, Sample processing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR?
The most frequently recorded therapeutic areas are Gastroenterology, Gynecology, Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR conducted?
The linked trials record locations in 13 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR delivered services.
What can this page tell me about IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- IMD Institut fuer Medizinische Diagnostik Berlin-Potsdam GbR